MTOR and plasma cell myeloma: To the best of our knowledge, this study is one of the few studies that have been done to evaluate the IHC expression of RGS1 and mTOR in BM biopsies of MM patients [11,30,34] and the first study to highlight the role of these markers in Egyptian multiple myeloma patients.